IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

This symposium took place on 10th June 2015 as part of EULAR 2015, the Annual European Congress of Rheumatology representing the official annual meeting of the European League Against Rheumatism (EULAR), in Rome, Italy

Chairperson: Philip Mease1
Speakers: Erik Lubberts,2 Iain McInnes,3 Désirée van der Heijde4

1. Swedish Hospital Medical Centre and the University of Washington School of Medicine, Seattle, Washington, USA
2. Erasmus MC: University Medical Centre Rotterdam, Rotterdam, Netherlands
3. Institute of Infection, Immunity and Immunology, University of Glasgow, Glasgow, UK
4. Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

Disclosure: Philip Mease has received research grants, consultation fees and/or speaker honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB; Erik Lubberts has received support from Novartis, Roche, Janssen, AbbVie, NTRC, Ensemble Therapeutics Group, and Pieris AG; Iain McInnes has received research funding and honoraria from Janssen, Eli Lilly, Amgen, Pfizer, Bristol-Myers Squibb, and Novartis; Désirée van der Heijde has received consulting fees and/or research grants from AbbVie, Amgen, AstraZeneca, Augurex, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB, and Vertex, and is a director of Imaging Rheumatology BV.
Acknowledgements: Writing assistance was provided by Dr Jill Powell, apothecom scopemedical Ltd.
Support: The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.
Citation: EMJ Rheumatol. 2015;2[1]:55-64.

Meeting Summary

Prof Philip Mease introduced psoriatic arthritis (PsA) with a particular emphasis on disease symptoms and an update on the status of current disease management. Erik Lubberts described the interleukin (IL)-17 pathway and its role in the pathogenesis of PsA. Prof Iain McInnes reviewed the clinical evidence for the efficacy of IL-17 inhibition in PsA. Prof Désirée van der Heijde brought the symposium to a close with a presentation on the clinical impact of joint structural damage and strategies for its prevention in PsA.

Download (PDF, 1.44MB)

Comments are closed.